A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization

Fiona Young, Julia A Critchley, Lucy K Johnstone, Nigel C Unwin, Fiona Young, Julia A Critchley, Lucy K Johnstone, Nigel C Unwin

Abstract

Background: Africa is facing a rapidly growing chronic non-communicable disease burden whilst at the same time experiencing continual high rates of infectious disease. It is well known that some infections increase the risk of certain chronic diseases and the converse. With an increasing dual burden of disease in Sub Saharan Africa the associations between diseases and our understanding of them will become of increased public health importance.

Aims: In this review we explore the relationships reported between tuberculosis and diabetes mellitus, human immunodeficiency virus, its treatment and metabolic risk. We aimed to address the important issues surrounding these associations within a Sub Saharan African setting and to describe the impact of globalization upon them.

Findings: Diabetes has been associated with a 3-fold incident risk of tuberculosis and it is hypothesised that tuberculosis may also increase the risk of developing diabetes. During co-morbid presentation of tuberculosis and diabetes both tuberculosis and diabetes outcomes are reported to worsen. Antiretroviral therapy for HIV has been associated with an increased risk of developing metabolic syndrome and HIV has been linked with an increased risk of developing both diabetes and cardiovascular disease. Globalization is clearly related to an increased risk of diabetes and cardiovascular disease. It may be exerting other negative and positive impacts upon infectious and chronic non-communicable disease associations but at present reporting upon these is sparse.

Conclusion: The impact of these co-morbidities in Sub Saharan Africa is likely to be large. An increasing prevalence of diabetes may hinder efforts at tuberculosis control, increasing the number of susceptible individuals in populations where tuberculosis is endemic, and making successful treatment harder. Roll out of anti-retroviral treatment coverage within Sub Saharan Africa is an essential response to the HIV epidemic however it is likely to lead to a growing number of individuals suffering adverse metabolic consequences. One of the impacts of globalization is to create environments that increase both diabetes and cardiovascular risk but further work is needed to elucidate other potential impacts. Research is also needed to develop effective approaches to reducing the frequency and health impact of the co-morbidities described here.

References

    1. WHO The Global Burden of Disease: 2004 update Switzerland. 2004 doi: 10.1038/sj.embor.7400699.
    1. Hadley C. The infection connection: Helicobacter pylori is more than just the cause of gastric ulcers-it offers an unprecedented opportunity to study changes in human microecology and the nature of chronic disease. EMBO rep. 2006;7:470–473. doi: 10.1007/s00125-006-0208-5.
    1. McNally R, Feltbower R, Parker L, Bodansky H, Campbell F, McKinney P. Space-time clustering analyses of type 1 diabetes among 0- to 29-year-olds in Yorkshire, UK. Diabetologia. 2006;49:900–904. doi: 10.1086/519841.
    1. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, Meer JW van der, van Crevel R. The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases. 2007;45:428–435. doi: 10.1159/000050578.
    1. Bacakoglu F, Basoglu O, Cok G, Sayiner A, Ates M. Pulmonary Tuberculosis in Patients with Diabetes mellitus. Respiration. 2001;68:595–600. doi: 10.1210/jc.2002-020794.
    1. Chen D, Misra A. Lipodystrophy in human immunodeficiency virus-infected patients. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4845–4856. doi: 10.1210/jc.2002-020794.
    1. Falasca K, Ucciferri C, Manzoli L, Mancino P, Pizzigallo E, Conti P, Vecchiet J. Metabolic Syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol. 2007;20:519–527. doi: 10.1038/ncpendmet0587.
    1. Falutz J. Therapy insight:body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Prac Endocrinol Metab. 2007;3:651–661. doi: 10.1056/NEJMra041811.
    1. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. New England Journal of Medicine. 2005;352:48–62. doi: 10.1371/journal.pmed.0050152.
    1. Jeon C, Murray M. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. PLoS Med. 2008;5:e152. doi: 10.1007/s11883-008-0010-6.
    1. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10:61–70. doi: 10.1177/1742395307081502.
    1. Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, Unwin NC. Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illness. 2007;3:228–245. doi: 10.1177/1742395307081502.
    1. Tamura M, Shirayama R, Kasahara R. A study on relation between active pulmonary tuberculosis and underlying diseases. Kekkaku. 2001;76:619–624. doi: 10.1016/0041-3879(90)90040-F.
    1. Mugusi F, Swai AB, Alberti KG, Melarty G. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle. 1990;71:271–276. doi: 10.1016/0041-3879(90)90010-6.
    1. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle. 1990;71:135–138. doi: 10.1186/1471-2458-7-234.
    1. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, Unwin NC. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health. 2007;7:234. doi: 10.1111/j.1742-1241.2006.01267.x.
    1. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin Resistance and HIV infection: a review. International Journal of Clinical Practice. 2007;61:463–472. doi: 10.1097/00002030-199807000-00003.
    1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58. doi: 10.1097/00002030-199807000-00003.
    1. Morton R, (Ed) Phthisiolgia: or a treatise of consumptions. London: Smith and Walford; 1694.
    1. Brock BL. The diabetic patient with tuberculosis. Lancet. 1957;77:238–242.
    1. Ferrara MA. The tuberculous diabetic patient. N Engl J Med. 1952;246:55–56.
    1. UK Department of Health . Stopping tuberculosis in England: an action plan from the chief Medical Officer. COI Communications for the Department of Health; 2004. Gateway ref: 1176.
    1. The STOP TB Partnership . Stop TB Partnership and World Health Organization Global Plan to Stop TB 2006-2015. World Health Organization, Switzerland; 2006.
    1. Tuberculosis Coalition for Technical Assistance . International standards for Tuberculosis care (ISTC) The Hague: Tuberculosis Coalition for Technical Assistance; 2006.
    1. UN . The Millennium Development Goals Report 2007. United Nations Department of Economic and Social Affairs (DESA); 2007.
    1. WHO report Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland. 2008 doi: 10.2105/AJPH.87.4.574.
    1. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2006;10:696–700.
    1. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health. 1997;87:574–579. doi: 10.2337/diacare.27.7.1584.
    1. Perez A, Brown HS, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg. 2006;74:604–611. doi: 10.1017/S0950268806006935.
    1. Ponce-De-Leon A, Garcia-Garcia L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Gustavo O, Rojas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M, et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care. 2004;27:1584–1590. doi: 10.1007/BF02148551.
    1. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B, McCormick JB. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect. 2007;135:483–491. doi: 10.1017/S0950268806006935.
    1. Englebach K. Passagerer Diabetes Mellitus bei 2 Tuberkulosekranken. [Transitory diabetes mellitus in two tuberculotics.] Journal Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1954;110:470–473. doi: 10.1007/BF02148551.
    1. Nichols GP. Diabetes among young tuberculous patients; a review of the association of the two diseases. Am Rev Tuberc. 1957;76:1016–1030. doi: 10.1111/j.1574-695X.1999.tb01397.x.
    1. Karachunski MA, Iakovleva OB, Belglarian MP. Clinical aspects of pulmonary tuberculosis in patients with borderline disorder of carbohydrate metabolism. Probl Tuberk. 1993;10:16–17. doi: 10.1084/jem.159.2.463.
    1. Joint Formulary Committee, British National Formulary, British Medical Association, Royal Pharmaceutical Society of Great Britain . British National Formulary. Vol. 56. London: BMJ and RPS; 2008.
    1. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunolo Med Microbiol. 1999;26:259–265. doi: 10.1016/0002-9343(82)90511-3.
    1. Prud'homme GJ, Fuks A, Colle E, Seemayer TA, Guttmann RD. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med. 1984;159:463–478. doi: 10.1084/jem.159.2.463.
    1. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med. 1982;72:439–450. 1.
    1. Tsukaguchi K, Yoneda T, Yoshikawa M. Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production by peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis. Kekkaku. 1992;67:755–760.
    1. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology: The immune system in health and disease. Vol. 6. Garland Science, New York; 2004.
    1. Madigan M, Martinko J, Parker J. Brock Biology of Microorganisms. Vol. 10. Pearson Education, London; 2002.
    1. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI, Trackers. TNST Type 2 diabetes and multidrug-resistant tuberculosis. Scandinavian Journal of Infectious Diseases. 2008;40:888–893. doi: 10.1080/00365540802342372.
    1. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Infect Dis Clin North Am J Med. 1995;9:65–96.
    1. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48:1247–1257. doi: 10.1007/s00125-005-1802-7.
    1. Ramachandran G, Santha T, Garg R, Baskaran D, Iliayas SA, Venkatesan P, Fathima R, Narayanan PR. Vitamin A levels in sputum-positive pulmonary tuberculosis patients in comparison with household contacts and healthy 'normals'. The International Journal of Tuberculosis and Lung Disease. 2004;8:1130–1133.
    1. Vijayamalini M, Manoharan S. Lipid peroxidation, vitamins C, E and reduced glutathione levels in patients with pulmonary tuberculosis. Cell Biochem Funct. 2004;22:19–22. doi: 10.1002/cbf.1039.
    1. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89:552–572. doi: 10.1079/BJN2003837.
    1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823. doi: 10.2337/diacare.27.3.813.
    1. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002;6:1114–1117.
    1. Patel JC, De Souza C, Jigjini SS. Diabetes and tuberculosis. Indian Journal of Tuberculosis. 1977;24:155–158.
    1. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis. 2003;7:58–64.
    1. Sosman MC, Steidl JH. Diabetic tuberculosis. Am J Roentgenol. 1927;17:625.
    1. Martens GW, Arikan MC, Lee J, Ren F, Greiner D. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol. 2007;37:518–524. doi: 10.1165/rcmb.2006-0478OC.
    1. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, Ven AJ van der, Danusantoso H, Aarnoutse RE, van Crevel R. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848–854. doi: 10.1086/507543.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S.
    1. The IDF consensus worldwide definition of the Metabolis Syndrome
    1. Chen LF, Hoy J, Lewin SR. Ten years of highly active therapy for HIV infection. Med J Aust. 2007;186:146–151.
    1. Mallal SA, John M. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316. doi: 10.1097/00002030-200007070-00002.
    1. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350:1596. doi: 10.1016/S0140-6736(05)64011-1.
    1. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, Igoudjil A, Guimont M-C, Biour M, Pessayre D, Fromenty B. Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments. Antimicrob Agents Chemother. 2003;47:3384–3392. doi: 10.1128/AAC.47.11.3384-3392.2003.
    1. Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471. doi: 10.1097/00002030-199903110-00004.
    1. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) J Acquir Immune Defic Syndr. 2005;40:119–120. doi: 10.1097/01.qai.0000187137.34789.dd.
    1. Moreno SA, Martinez EB. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors. AIDS. 2000;14:905–906. doi: 10.1097/00002030-200005050-00024.
    1. Wohl DA. Considering metabolic issues when initiating HIV therapy. Current HIV/AIDS Reports. 2007;4:119–125. doi: 10.1007/s11904-007-0018-5.
    1. Fève B, Glorian M, Hadri KE. Pathophysiology of the HIV-Associated Lipodystrophy Syndrome. Metab Syndr Relat Disord. 2004;2:274–286. doi: 10.1089/met.2004.2.274.
    1. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS. 1998;1:1393–1394.
    1. Grunfeld C. Insulin Resistance in HIV infection: drugs, host responses, or restoration to health? Topics in HIV Medicine. 2008;16:89–93.
    1. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin. 2008;24:609–624. doi: 10.1185/030079908X272742.
    1. Blümer R, van Vonderen M, Sutinen J, Hassink E, Ackermans M, van Agtmael M, Yki-Jarvinen H, Danner S, Reiss P, Sauerwein H. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227–236. doi: 10.1097/QAD.0b013e3282f33557.
    1. Magula NP, Mayosi BM. Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr. 2003;14:231–237.
    1. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349–1353. doi: 10.1161/01.CIR.0000120707.98922.E3.
    1. Dye C. Global epidemiology of tuberculosis. Lancet. 2006;367:938–940. doi: 10.1016/S0140-6736(06)68384-0.
    1. International Diabetes Federation . Diabetes Atlas. 3 2006.
    1. 2007 AIDS Epidemic Update. Chapter two overview of the global AIDS epidemic
    1. Unwin NC, Alberti KG. Diabetes and the good, the bad and the ugly of globalization. Int Diabetes Monitor. 2007;19:6–11.
    1. United Nations Population Division UN . An overview of urbanization, internal migration, population distribution and development in the world. UN, New York; 2008.
    1. UN-HABITAT . State of the World's Cities: Trends in Sub-Saharan Africa. UN-HABITAT. Nairobi; 2004.
    1. Unwin N, Alberti KG. Chronic non-communicable diseases. Annals of Tropical Medicine & Parasitology. 2006;100:455–464. doi: 10.1179/136485906X97453.
    1. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. Circulation. 2005;112:3592–3601. doi: 10.1161/CIRCULATIONAHA.105.544312.
    1. Sobngwi E, Mbanya JC, Unwin NC, Porcher R, Kengne AP, Fezeu L, Minkoulou EM, Tournoux C, Gautier JF, Aspray TJ, et al. Exposure over the life course to an urban environment and its relation with obesity, diabetes, and hypertension in rural and urban Cameroon. Int J Epidemiol. 2004;33:769–776. doi: 10.1093/ije/dyh044.
    1. Hawkes C. The role of foreign direct investment in the nutrition transition. Public Health Nutrition. 2005;8:357–365. doi: 10.1079/PHN2004706.
    1. Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutrition Reviews. 1997;55:31–43.
    1. Mbanya JC, Ngogang J, Salah JN, Minkoulou E, Balkau B. Prevalence of NIDDM and Impaired Glucose Tolerance in a Rural and an Urban Population in Cameroon. Diabetologia. 1997;40:824–829. doi: 10.1007/s001250050755.
    1. Aspray TJ, Mugusi F, Rashid S, Whiting D, Edwards R, Alberti KG, Unwin NC. Essential Non-Communicable Disease Health Intervention Project. Rural and urban differences in diabetes prevalence in Tanzania: the role of obesity, physical inactivity and urban living. Trans R Soc Trop Med Hyg. 2000;94:637–644. doi: 10.1016/S0035-9203(00)90216-5.
    1. Organization for Economic Co-operation and Development . Database on immigrants and expatriates. Paris: OECD; 2005.
    1. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary. Clinical Infectious Diseases. 2007;44:981–987. doi: 10.1086/512371.
    1. Akokpari J. Globalisation and Migration in Africa. African Sociological Review. 2000;4:72–92.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit